Trial Profile

Phase I/II Dose-Finding, Safety, Tolerance, and Pharmacokinetics Study of a Raltegravir-Containing Antiretroviral Therapy (ART) Regimen in HIV-Infected and TB Co-Infected Infants and Children

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 22 Jul 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Raltegravir (Primary) ; Antiretrovirals; Rifampicin
Indications HIV-1 infections
Focus Adverse reactions; Pharmacokinetics

Most Recent Events

11 Mar 2020 Results from Cohort 3 (4 wks to <2 yrs) using RAL chewable tablets as a dispersible tablet presented at the 27th Conference on Retroviruses and Opportunistic Infections
11 Dec 2019 Status changed from active, no longer recruiting to completed.
15 Nov 2019 Results (n=26) in HIV-infected infants and children receiving ART and RIF-containing therapy for TBpublished in the AIDS

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com